References Company Profile


RegiSCAR es el último de una serie de estudios multinacionales sobre reacciones cutáneas severas a medicamentos. Muchos colaboradores y participantes activos han publicado a lo largo de los años un número importante de artículos que analizan el tema desde ángulos diferentes. La lista que figura a continuación es simplemente un resumen somero de algunas de dichas publicaciones

Lista de publicaciones

Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, Tsai SH, Wu TL, Bellon T, Ramouza R, Fortier C, Toubert A, Charron D, Hovnanian A, Wolkenstein P, Chung WH, Mockenhaupt M, Roujeau JC. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. The Pharmacogenomics J. 2013 Dec 10. doi: 10.1038/tpj.2013.40. [Epub ahead of print]

Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeau JC; The RegiSCAR study group. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013 Nov; 169(5): 1071-80.

Komorowski L, Mockenhaupt M, Sekula P, Roujeau JC, Probst C, Teegen B, Li W, Stöcker W, Zillikens D. Lack of a Specific Humoral Autoreactivity in Sera From Patients With Early Erythema Exsudativum Multiforme Majus. J Invest Dermatol. 2013 Dec;133(12):2799-802.

Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, Roujeau JC, Sekula P, Simpson MA, Trembath RC, Mockenhaupt M, Smith CH. Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis J Invest Dermatol. 2013 Jul;133(7):1904-7.

Haddad C, Sidoroff A, Kardaun SH, Mockenhaupt M, Creamer D, Dunant A, Roujeau JC. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Are Drug Dictionaries Correctly Informing Physicians Regarding the Risk? Drug Saf. 2013 Aug;36(8):681-6.

Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC; RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013 May;133(5):1197-204.

Lipowicz S, Sekula P, Ingen-Housz-Oro S, Liss Y, Sassolas B, Dunant A, Roujeau JC, Mockenhaupt M. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2013 Apr;168(4):726-32

Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, Naldi L, Halevy S, Roujeau JC. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol. 2012 Sep;167(3):555-62.

Tang YH, Mockenhaupt M, Henry A, Bounoua M, Naldi L, Le Gouvello S, Bensussan A, Roujeau JC. Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. Clin Exp Allergy. 2012;42:248-54.

Genin E, Schumacher M, Roujeau JC, Naldi L, Liss Y, Kazma R, Sekula P, Hovnanian A, Mockenhaupt M. Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe. Orphanet J Rare Dis. 2011 Jul 29;6:52

Kelly JP, Kaufman DW, Dunant A, Mockenhaupt M, Roujeau JC. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. J Am Acad Dermatol. 2011 Jun;64(6):1193-4.

de Araujo E, Dessirier V, Laprée G, Valeyrie-Allanore L, Ortonne N, Stathopoulos EN, Bagot M, Bensussan A, Mockenhaupt M, Roujeau JC, Tsapis A. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol. 2011 Feb;20(2):107-12

Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011 Mar;127(3 Suppl):S60-6.

Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau JC, Kardaun S, Naldi L, Schumacher M, Mockenhaupt M. Evaluation of SCORTEN on a Cohort of Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Included in the RegiSCAR Study. J Burn Care Res. 2011 March/April;32(2):237-245.

Halevy S, Kardaun SH, Davidovici B, Wechsler J; EuroSCAR and RegiSCAR study group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol. 2010;163:1245-52

Sassolas B, Haddad C, Mockenhaupt M Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H.. ALDEN, an Algorithm for Assessment of Drug Causality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case-Control Analysis. Clin Pharmacol Ther. 2010;88:60-8

Sekula P, Caputo A, Dunant A Roujeau JC, Mockenhaupt M, Sidoroff A, Schumacher MAn application of propensity score methods to estimate the treatment effect of corticosteroids in patients with severe cutaneous adverse reactions. Pharmacoepidemiol Drug Saf. 2010;19:10-8

Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, Martin E, Kaufman DW, Maison P. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-304.

Valeyrie-Allanore L, Poulalhon N, Fagot JP Sekula P, Davidovici B, Sidoroff A, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiother Oncol. 2008 ;87:300-3.

Lonjou C, Borot N, Sekula P. Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M; RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99-107.

Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33-40.

Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC; EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25-32.

Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35-44.

Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, Mockenhaupt M, Fagot JP, Roujeau JC. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157:989-96.

Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156:609-11.

Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC; RegiSCAR Group. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 2006;6:265-8.

Mockenhaupt M, Roujeau JC. EMPACT syndrome. J Dtsch Dermatol Ges. 2005;3:569-70.

Mockenhaupt M, Kelly JP, Kaufman D, Stern RS; SCAR Study Group. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol. 2003;30:2234-40.

Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC; SCAR Study Group. Severe Cutaneous Adverse Reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019-24

Viboud C, Boëlle PY, Kelly J, Auquier A, Schlingmann J, Roujeau JC, Flahault A. Comparison of the statistical efficiency of case-crossover and case-control designs: application to severe cutaneous adverse reactions. J Clin Epidemiol. 2001;54:1218-27.

Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC; EuroSCAR Study Group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001;15:1843-8.

Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol. 2001 Mar;28(3):113-9.

Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet. 1999;353:2190-4.

Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-7.

Kelly JP, Auquier A, Rzany B, Naldi L, Bastuji-Garin S, Correia O, Shapiro S, Kaufman DW. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol. 1995;48:1099-108

Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs.N Engl J Med. 1994;331:1272-85.

Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-6